Abstract

Govender P. S.* and Abdel Goad E. H.

The introduction of targeted therapies has offered the promise of better survival outcomes for patients with metastatic renal cell carcinoma. Sunitinib malate, an oral, multitargeted tyrosine kinase inhibitor, is an important treatment option for patients with metastatic renal cell carcinoma. This case study explores the controversial use of sunitinib in a patient with a non-clear cell variant of renal cell carcinoma, also on treatment with combined antiretroviral treatment for a co-existing human immunodeficiency virus infection.